Posttranslational Modification of 6-phosphofructo-1-kinase as an Important Feature of Cancer Metabolism by Šmerc, Andreja et al.
Posttranslational Modification of 6-phosphofructo-1-
kinase as an Important Feature of Cancer Metabolism
Andreja S ˇmerc, Eva Sodja
¤, Matic Legis ˇa*
Department of Biotechnology, National Institute of Chemistry, Ljubljana, Slovenia
Abstract
Background: Human cancers consume larger amounts of glucose compared to normal tissues with most being converted
and excreted as lactate despite abundant oxygen availability (Warburg effect). The underlying higher rate of glycolysis is
therefore at the root of tumor formation and growth. Normal control of glycolytic allosteric enzymes appears impaired in
tumors; however, the phenomenon has not been fully resolved.
Methodology/Principal Findings: In the present paper, we show evidence that the native 85-kDa 6-phosphofructo-1-kinase
(PFK1), a key regulatory enzyme of glycolysis that is normally under the control of feedback inhibition, undergoes
posttranslational modification. After proteolytic cleavage of the C-terminal portion of the enzyme, an active, shorter 47-kDa
fragment was formed that was insensitive to citrate and ATP inhibition. In tumorigenic cell lines, only the short fragments
but not the native 85-kDa PFK1 were detected by immunoblotting. Similar fragments were detected also in a tumor tissue
that developed in mice after the subcutaneous infection with tumorigenic B16-F10 cells. Based on limited proteolytic
digestion of the rabbit muscle PFK-M, an active citrate inhibition-resistant shorter form was obtained, indicating that a
single posttranslational modification step was possible. The exact molecular masses of the active shorter PFK1 fragments
were determined by inserting the truncated genes constructed from human muscle PFK1 cDNA into a pfk null E. coli strain.
Two E. coli transformants encoding for the modified PFK1s of 45,551 Da and 47,835 Da grew in glucose medium. The
insertion of modified truncated human pfkM genes also stimulated glucose consumption and lactate excretion in stable
transfectants of non-tumorigenic human HEK cell, suggesting the important role of shorter PFK1 fragments in enhancing
glycolytic flux.
Conclusions/Significance: Posttranslational modification of PFK1 enzyme might be the pivotal factor of deregulated
glycolytic flux in tumors that in combination with altered signaling mechanisms essentially supports fast proliferation of
cancer cells.
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Introduction
A consistent characteristic of malignant cells is the consumption
of a larger amount of glucose compared to that of normal cells and
the conversion of the majority of glucose into lactic acid. The tumor
cells preferentially use glycolysis over mitochondrial oxidative
phosphorylation for glucose-dependent ATP production even in
the presence of ample oxygen to fuel mitochondrial respiration. [1].
This deviant energetic metabolism, known as the ‘‘Warburg effect,’’
is therefore at the root of tumor formation and growth and has been
even discussed as a potential hallmark of cancer [2].
In the last decade, the discovery of oncogenes diverted interest
away from studies of cellular metabolism in tumors towards those
aimed at uncovering the function of oncogenes that control
metabolism. Thus far, the crucial factors recognized for producing
the cancer metabolic phenotype appear to be the oncogenic
mutations that alter growth factor signaling through the PI3K/
Akt/mTOR pathway [3]. Activation of this pathway enhances
metabolic activities of glycolysis by two major events. First, the
synthesis of the sugar transporter Glut1 is induced to facilitate
glucose uptake by the cells [4,5]. Second, the activity of
transcription complex HIF-1a is increased, which in cooperation
with transcription factor c-Myc enhances the synthesis of the
majority of glycolytic enzymes [6]. Increased amounts of the wild-
type enzymes consequently result in increased specific activities.
However, glycolytic flux in eukaryotic organisms is tightly
controlled by allosteric enzymes that retain their regulation by
feedback inhibition in spite of the elevated activities of interme-
diary enzymes. This statement has been confirmed by experiments
in E. coli [7] and S. cerevisiae [8], where overexpression of all
glycolytic enzymes had no effect on the rate of glucose
consumption and/or ethanol production. Therefore, one is forced
to conclude that important modifications of the kinetics of
regulatory enzymes must also be involved in metabolic changes
that occur during the transformation of normal mammalian cells
into cancer cells.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19645Glycolysis is central to primary metabolism, and normally, it is
tightly regulated by three allosteric enzymes, hexokinase, 6-
phosphofructo-1-kinase (PFK1) and pyruvate kinase (PK), which
catalyze individual irreversible steps. Hexokinase, involved in the
first regulatory step, appears predominantly in an HK2 isoenzyme
form in tumors that is bound to the mitochondrial outer
membrane facing the cytosol. Microlocation of this enzyme
enables preferential access to newly synthesized ATP for
phosphorylating glucose, and it is resistant to product inhibition
[9]. Another allosteric enzyme is pyruvate kinase, which regulates
metabolic flux over the terminal part of glycolysis. Tumor cells
have been shown to exclusively express the embryonic M2 isoform
of PK that can be activated by fructose-1,6-bisphosphate.
However, binding of tyrosine-phosphorylated peptides to PK-M2
results in the release of the allosteric activator, leading to inhibition
of enzymatic activity. Deactivation of PK-M2 in tumor cells is
believed to divert glucose metabolism from energy production to
anabolic processes [10].
However, the most complex control over glycolytic flux is
attributed to PFK1 (EC 2.7.1.11), which surmounts the regulatory
roles of the other two allosteric enzymes. PFK1 catalyzes the
phosphorylation of fructose-6-phosphate to fructose-1,6-bispho-
sphate, using MgATP as a phosphoryl donor [11]. PFK1 is
stimulated by fructose-2,6-bisphosphate (F-2,6-BP), ADP/AMP
and ammonium ions, whereas citrate and ATP act as strong
inhibitors [11,12].
During evolution, eukaryotic PFK1 enzymes developed by
duplication, tandem fusion and divergence of catalytic and effector
binding sites of a prokaryotic ancestor [12]. However, the strict
conservation between active site residues in the N-terminal
segment of the eukaryotic enzyme and those of bacterial PFKs
suggest that the active site of eukaryotic PFK1 is located only in
the N-terminal portion [12]. On the other hand, the allosteric
ligand binding sites that developed during evolution by mutations
in the C-terminus enable fine-tuning of the regulatory enzyme by
the elevated levels of specific downstream metabolites. One of the
allosteric ligands is citrate, which acts as a potent inhibitor of all
mammalian PFK1 isoforms. Studies on citrate allosteric sites in
rabbit muscle PFK1 concluded that these sites developed from the
phosphoenolpyruvate (PEP)/ADP allosteric site of Escherichia coli.
Amino acid residues forming the citrate allosteric site are located
both in the N- and C-termini of the molecule [13].
In mammalian genomes, three different PFK1 genes are present
and are differently expressed in individual tissues. In human
tissues, their protein products have the following molecular masses:
muscle type (PFK-M), 85,051 Da [14]; liver type (PFK-L)
84,917 Da [15]; and platelet type (PFK-P), 85,596 Da [16].
All three isoenzymes are strongly inhibited by citrate, with IC50
values of 0.08, 0.13 and 0.18 mM for brain (platelet), muscle, and
liver PFK1, respectively [17]. All human PFK1 isoforms are also
reported to be intensely inhibited by ATP concentrations higher
than 0.05 mM, yet (F-2,6-BP) can antagonise the negative effects
of ATP to some extent [18].
Currently, in cancer cells, the activity of the PFK1 enzymes is
believed to be up-regulated only by the loss of p53 function, which
results in the down-regulation of the TIGAR protein that acts as a
fructose-2,6-bisphosphatase [19]. Consequently, the level of F-2,6-
BP remained high in tumors and acted as a strong positive
stimulus.
However, a PFK1 isoform that was less sensitive to citrate
inhibition (Ki=0.75 mM citrate) and more sensitive to activation
by F-2,6-BP was described in human glioma [20]. A PFK1 isoform
with similar kinetic characteristics was also observed in the fast-
growing rodent AS-30D hepatoma cells, which showed complete
insensitivity towards its allosteric inhibitors, citrate and ATP, in
the presence of physiological concentrations of F-2,6-BP. In
addition, the enzyme was highly activated by its activators NH4
+,
AMP, and F-2,6-BP [21]. Yet, the nature of PFK1 isoforms
exhibiting changes in enzyme kinetics was not studied in detail.
A citrate inhibition-resistant form of PFK1 that was activated to
a higher level by allosteric activators has recently been described in
the commercially important fungus, Aspergillus niger [22–24]. These
kinetic characteristics were attributed to 49-kDa subunits, which
are relatively small PFK1 molecules with respect to other
eukaryotic PFK1s of approximately 85 kDa. Further studies
showed that the shorter 49-kDa fragments are formed by a two-
step posttranslational modification of the native 85-kDa enzyme
[23–25].
In the present report, we present evidence that a similar
posttranslational modification of the native muscle-type PFK1
may also occur in mammalian cancer cells that consequently leads
to the formation of active shorter PFK1 fragments with changed
kinetic parameters.
Results
Analyses of amino acid sequences of the human PFK-M
protein
The origin of mammalian genes encoding PFK1 enzymes by
duplication of prokaryotic ancestor genes [12] can be confirmed
by the alignment of amino acid residue sequences of the N- and C-
halves of the human PFK-M isoenzyme, showing substantial
homology (supplemental Fig. S1). Analysis conducted by CLUS-
TALW [26] revealed 25.4% identity, 21.6% strong similarity,
11.6% weak similarity and 41.8% difference among amino acid
residues of both halves of the primary structure.
The studies on posttranslational modification of A. niger PFK1
showed that the native enzyme was first cleaved by serine protease
to a shorter protein that was initially inactive, but regained activity
after the phosphorylation of a specific threonine residue that was
located in the enzyme active center [25]. A negatively charged
amino acid residue (phosphorylated threonine) was essential for
generating enzyme activity [25]. By replacing the codon for the
threonine residue with one for glutamic acid in the truncated A.
niger pfkA, the need for phosphorylation of initially inactive shorter
PFK1 fragments was eliminated and active shorter PFK1
fragments were encoded directly by the modified pfkA genes
[25]. By aligning the deduced amino acid sequences of three
human isoenzymes with that of the A. niger enzyme (supplemental
Fig. S2), a negatively charged amino acid residue (aspartic acid)
was found only in the sequence of PFK-M at the position
corresponding to the threonine residue in the A. niger protein. The
other two isoenzymes, PFK-L and PFK-P, contained a non-polar
alanine residue at the matching site. PFK-M with a negatively
charged aspartic acid residue at this critical locus was therefore
concluded to be the most likely candidate for generating active
shorter PFK1 fragments after a single posttranslational modifica-
tion step.
In vitro posttranslational modification of mammalian
PFK1
To verify that, PFK1 was isolated from rabbit muscle. The
purified enzyme was incubated with various proteases and tested
for the presence of newly generated, active, citrate inhibition-
resistant shorter PFK1 fragments. Various commercially available
proteases from various species were employed in individual
experiments.
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citrate, which functions as a strong inhibitor of the native enzyme but
not of the shorter fragments. After limited proteolysis of the purified
native PFK1 with Proteinase K (0.001 mg/ml), PFK1 activity was
detected. A gradual increase in PFK1 activity was detected in the
samples that wereexposed to proteolytic action for prolonged periods
of time (Fig. 1). With SDS-PAGE, fragments of approximately
45 kDa were observed after limited proteolysis with 0.001 mg/ml of
Proteinase K (supplemental Fig. S3), whereas incubation with
Proteinase K at a higher concentration (0.01 mg/ml) produced
inactive, slightly shorter fragments. No active fragments could be
detected after cleavage of the native enzyme with other commercially
available enzymes of microbial or mammalian origin.
This experiment primarily showed that a single-step posttrans-
lational modification of mammalian PFK1 was possible for
yielding active shorter PFK1 fragments. The protease that was
actually involved in the production of such fragments in human
cells remains to be determined, but the most likely candidates are
serine proteases that must be activated intracellularly.
Detecting short PFK-M fragments in metastatic tumor
cell lines by immunoblotting
To examine which PFK1 forms are present in tumor cells, four
different neoplastic cell lines that are known to induce metastatic
tumors after insertion into test animals were used. The following
cell lines were tested: human carcinoma HeLa cells; mouse
melanoma B16-F10 cells; and two lymphomas, the rat Nb2-11 line
and the human TF-1 line. For western blotting, an antibody raised
against an epitope of the enzyme’s active center that was identical
in various mammalian PFK1-M isoforms, but not in L or P
isoforms, was employed.
In the homogenates of all neoplastic cell lines, the amount of
native PFK1 of 85 kDa was below the immunoblotting detection
limit (Fig. 2). However, a number of lower molecular weight
fragments were spotted. In all cell homogenates, fragments of
approximately 47 kDa were present, while some other fragments
appeared sporadically. In contrast to the tumorigenic cell lines, only
the native 85 kDa PFK1 enzymes were observed in lymphocytes
isolated from peripheral human blood. Native enzymes were
predominant also in human kidney embryonic cells (HEK 293 cell
line) using an identical immunostaining method. HEK cells were
immortalized by adenovirus but were not tumorigenic. Although no
47 kDa low molecular weight fragment was detected in HEK cells,
some slightly shortened native enzyme forms were observed that
might be a product of alternative splicing. In human muscle, an
alternative transcript encoding a PFK-M isoenzyme has been
reported, yielding an active enzyme with 749 amino acid residues
and a molecular mass of 81,776 Da [27]. Evidence for alternative
splicing of the PFK-M gene has also been reported in mice [28].
In the control, no bands were observed when a sample of
growth medium was immunoblotted with the antibodies used for
PFK1 detection.
Detecting short PFK-M fragments in tumors by
immunoblotting
In a tumor that has developed in a C57BL/6 mouse, 10 days
after the subcutaneous injection of B16-F10 cells, nearly identical
fragments were detected as in B16-F10 cells growing in a tissue
culture (Fig. 3). However in a tumor, a strong band corresponding
to the native PFK-M enzyme was present that most probably
originated from non-tumorigenic supporting tissue such as blood
vessels, stroma or inflammatory cells. More detailed inspection of
the shorter fragments from B16-F10 cells and corresponding
tumor revealed that 47 kDa fragment was present in individually
growing cells while those that developed in a tumor expressed a
45 kDa fragment.
Truncated human muscle PFK1 cDNA encodes active
shorter PFK-M fragments in E.coli cells with disrupted
native pfkA
In the next step, the efficiency of active shorter human PFK-M
fragments was tested in an E. coli strain that lacked its own native
Figure 1. PFK1 activities after limited proteolytic degradation of native rabbit PFK1 by Proteinase K. Activities of the native PFK1
isolated from rabbit muscle after limited proteolysis by Proteinase K (dark) and untreated native enzyme (light) as measured in a system containing
5 mM citrate. Data are representative of three independent measurements and are presented as means 6 standard deviation.
doi:10.1371/journal.pone.0019645.g001
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fragments could not be determined from western blots, a series of
truncated genes were prepared from human muscle PFK1 cDNA.
Truncated genes were inserted into the E. coli RL 257 [29] strain,
and transformants were tested for altered growth characteristics on
a medium containing glucose. The proteins encoded by truncated
genes differed by several amino acid residues and covered
molecular masses ranging from 45 kDa to 46 kDa and 47 kDa
to 48 kDa (supplemental Table S2). Two transformants able to
grow on supplemented glucose minimal medium were revealed,
one from each group of molecular masses (Fig. 4). The first strain
synthesized Fragment number 4 (supplemental Table S2) with 422
amino acid residues and a molecular mass of 45,551 Da, whereas
the other strain encoded Fragment number 9 (supplemental Table
S2) with 443 amino acid residues and a mass of 47,835 Da. The
cells of both strains multiplied to an optical density of 2 in
approximately 24 hours, which indicated that both recombinant
proteins were active and able to effectively participate in bacterial
metabolism. No growth of transformants encoding other shorter
PFK-M fragments could be observed, although synthesized
recombinant proteins were detected by western blots (supplemen-
tal Fig. S4). No growth on glucose medium could be detected by a
control, the parental RL257 strain carrying the pALTER-Ex1
plasmid with no gene inserted. Surprisingly, the transformant
encoding the native human PFK-M (85,051 Da) was unable to
proliferate under identical conditions, although high enzymatic
activity (more than 600 mU/ml) was detected in the cell-free
extract.
In both transformants that were able to grow on glucose
medium, PFK1 activity was detected in the homogenates. In both
transformants that were able to grow on glucose medium, PFK1
activities were detected in the homogenates. In the transformant
encoding Fragment 9, activity resistant to ATP and citrate
inhibition was recorded at 0,5 mM of F6P which is near
physiological concentration [30]. The Fragment 9 showed high
affinity toward the ATP (Km of about 0.05 mM) while at
Figure 2. Western blots of homogenates of four tumorigenic cell lines, HEK immortalized cells and lymphocytes immunostained
with PFK-M anti-bodies. Western blots of four tumorigenic cell lines (above) showed the presence of fragments of different lengths, with a
fragment of 47 kDa regularly present, while no native 85-kDa PFK1 could be observed. In non-neoplastic cell lines (below) (HEK cells), the native PFK1
forms were predominant, while in normal lymphocytes isolated from peripheral human blood only a single protein band was detected corresponding
to 85 kDa native PFK1. In the Western blot of lymphocytes two volumes of cell lysate were applied to the gel: 10 ml (left), and 20 ml (right).
doi:10.1371/journal.pone.0019645.g002
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detected (Fig. 5A). On the contrary, the recombinant human
native 85 kDa PFK-M isolated from E.coli RL257 strain showed a
peak in the enzyme activities at increasing concentrations of ATP.
At low ATP concentrations the activities rose more slowly in
respect to the shorter fragment, indicating lower affinity of the
native enzyme toward the ATP (Km,0,3 mM). However, ATP
concentrations above 0,6 mM caused a sharp decrease of the
native enzyme activity and only a modest PFK1 activity was
detected at ATP concentration of 1 mM (Fig. 5A). Sodium citrate
didn’t inhibit the activity of the shorter PFK-M fragment (Fig. 5B).
This is in contrast to the kinetic characteristics of the recombinant
human native PFK-M enzyme where a strong sensitivity toward
the citrate was revealed [31]. No inhibition of the shorter fragment
with lactate could be detected either (Fig. 5B), a metabolite that
was recently proposed to down regulate mouse PFK1 activities
[32].
Fructose-6-phosphate saturation curves without and with F-2,6-
BP showed a change in PFK-M activities of both the native
enzyme (Fig. 6A) and the Fragment 9 (Fig. 6B). By adding F-2,6-
BP to the measuring system, a sigmoid plot was converted to
Michaelis-Menten kinetics, characterized by a steep rise in
activities with respect to substrate concentration. Although F-
2,6-BP increased the affinity of both enzymes toward the F6P as a
substrate, the activator also caused a marked increase in maximal
velocity of the shorter Fragment 9 (Fig. 6B) while no such effect
could be recorded with the native enzyme (Fig. 6A).
The shorter PFK-M fragments appeared to be extremely
unstable in the in vitro conditions. The activity could be stabilized
to a certain extent in a cell-free extract that contained about
10 mg of proteins per ml by adding fructose-6-phosphate to a final
concentration of 6 mM. However, rapid deactivation was
recorded in the measuring vial (supplemental Fig. S5) when the
amount of dissolved proteins was significantly reduced. After
approximately 10 minutes of incubation at 30uC, no NADH
consumption could be detected in the system.
Figure 3. Western blots of B16-F10 cells growing as a tissue
culture and B16-F10 cells that formed a tumor in mouse,
immunostained with PFK-M anti-bodies. No native PFK1 enzyme
was detected in the cells growing in a tissue culture, while in a tumor, a
strong signal corresponding to the native enzyme was present. Shorter
fragments were detected in both homogenates with a 47 fragment
present in individually growing cells and a 45 kDa fragment present in a
tumor tissue.
doi:10.1371/journal.pone.0019645.g003
Figure 4. Growth of two E.coli transformants encoding two different human shorter PFK-M fragments. Two E.coli transformants
encoding Fragment 4 (X) and Fragment 9 (%) were able to grow in supplemented glucose minimal medium. No growth of the parental strain, RL
257, carrying the pALTER-Ex-1 plasmid with no inserted gene (N) could be detected. Data are representative of three independent measurements
and are presented as means 6 standard deviation.
doi:10.1371/journal.pone.0019645.g004
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cells promotes growth, glucose consumption and lactate
production
To determine whether modified PFK-M enzymes have similar
physiological effects in non-tumorigenic human cells (Flp-in T-Rex
HEK 293 cell line), stable transfectants were prepared that
enabled constitutive expression of hpfkM encoding the native PFK-
M and hpfkMFrg9 encoding the PFK-M Fragment 9. Growth rate,
glucose consumption and lactate accumulation were compared
with those in transfectants carrying integrated empty plasmid
under identical growth conditions. The cells expressing hpfkM and
hpfkMFrg9 proliferated more rapidly compared to the parental
cells, as observed on semi-logarithmic graph, however detailed
analyses of a linear plot of the same data suggested a slightly
shorter lag phase of transfected cells with respect to the parental
strain (Fig. 7A). The most drastic difference among tested
transfectants was observed for lactate excretion. At 24 hours of
incubation, the amount of lactate accumulated in the medium and
normalized to 1 million cells revealed four folds higher
productivity by the strain synthesizing Fragment 9 with respect
to the strain encoding the native PFK-M and six folds higher in
comparison to the parental strain. At day two, the amount of
lactate accumulated was still about 30% higher by the cells with
Figure 5. PFK1 activity of a recombinant shorter PFK-M fragment and native PFK-M enzyme with respect to some inhibitors. In
figure 5A relative specific PFK1 activities detected in the homogenate of the transformant encoding Fragment 9 (% ) and with native PFK-M enzyme
isolated from E.coli transformant (#) are shown, that were measured at increasing concentrations of ATP. In figure 5B specific PFK1 activities were
measured in the homogenate of the transformant encoding Fragment 9 without inhibitor (%), in the presence of 5 mM Na3-citrate (e), and with
5 mM Na-lactate (D). All measurements were conducted with 0.5 mM of F6P. Data are representative of at least three independent measurements
and are presented as means 6 standard deviation.
doi:10.1371/journal.pone.0019645.g005
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three tested cell lines (Fig. 7C). Increased lactate production by the
cells expressing the hpfkMFrg9 gene was reflected also in the
glucose consumption rates. At 24 hours, the highest amount of
glucose, normalized to the fixed cell number, has been taken up by
the cells encoding the Fragment 9, about 40% less glucose was
consumed by the cells synthesizing the native PFK-M enzyme,
while the parental cells metabolized even less glucose (Fig. 7B).
Discussion
A variety of oncogenes, including Akt [33], BCR-Abl [34], c-
Myc and HIF [35], promote glucose metabolism in cancer cells.
However, the activation of Akt alone, which encodes a serine/
threonine kinase that is under the control of phosphatidylinositide-
3-kinase PI3K, has been proven sufficient to stimulate the switch
to aerobic glycolysis [36]. However, the underlying molecular
changes at the level of regulatory glycolytic enzymes remain poorly
understood. Constitutive activation of Akt has been implicated in
the regulation of cell proliferation [37] and suggested to participate
in promoting Glut1 transporter activity [4]. Moreover, the
stimulating role of the PI3K/Akt signaling pathway has been
reported in hormone-dependent proteolytic induction (kallikrein
gene expression) in breast [38] and prostate [39] cancer cell lines.
Human tissue kallikreins belong to a subgroup of serine proteases
that are similar to Proteinase K, which we have demonstrated here
Figure 6. PFK1 activity of a recombinant shorter PFK-M fragment and native PFK-M enzyme with respect to F-2,6-BP as an
activator. In figure 6A F6P saturation curves of the isolated native PFK-M enzyme with (#) and without (e)4mM of F-2,6-BP are presented. In
figure 6B F6P saturation curves detected in the homogenate of the transformant encoding Fragment 9 with (%) and without (D)4mM of F-2,6-BP are
shown. The measurements were conducted with 1 mM of ATP. In both graphs relative specific activities are shown. Data are representative of at least
three independent measurements and are presented as means 6 standard deviation.
doi:10.1371/journal.pone.0019645.g006
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resistant shorter PFK1 fragments. Therefore, Akt-mediated
induction of aerobic glycolysis might also be involved in the
posttranslational modification of PFK1 by activating proteolytic
enzymes.
This assumption is supported by the similar results obtained
with transfected cells constitutively expressing Akt [36] and the
cells synthesizing highly active shorter PFK1 fragments in this
study. Both types of cells consumed glucose more rapidly and
excreted lactate in higher yields compared to the un-transfected
cells.
With Western blotting experiments of tumorigenic and normal
cells no native 85 kDa enzyme could be detected in neoplastic
cells, whereas a fragment of 47 kDa was characteristically present.
However, some other smaller fragments were spotted as well. They
most probably originated from the native PFK1 since the antibody
used, proved to be specific enough and no low molecular peptides
appeared in the lysate of lymphocytes and HEK cells. Besides,
little is known about the cytosolic proteolytic activity in cancer cells
therefore it is difficult to speculate about the number of proteases
that might attack the PFK1 enzyme. Undoubtedly, better
information about the posttranslational modification would be
achieved by using an epitope-tagged PFK1 allele. In fact we tested
AU1 epitope tag [40] that was N-terminally fused to the native
PFK-M. Although tagged pfk-M gene was expressed and protein
detected, no enzyme activity could be detected (data not shown).
We believe that the extension of six amino acid residues influenced
the folding of the protein in the cells and prevented the correct
association of monomeres into an active tertameric holoenzyme.
Unfortunately, inactive enzyme could not be employed for the
studies of posttranslational modification by proteolytic cleavage.
Interestingly, slightly different shorter fragments were detected
in B16-F10 cells growing individually and in a tumor tissue.
Though, in vivo experiments conducted in E.coli transformants
revealed that both 45 and 47 kDa PFK-M fragments could
associate into an active holoenzyme. This observation suggested
that different environmental conditions might influence the
posttranslational modification of PFK-M in B16-F10 cells.
After posttranslational modification of PFK-M, enzyme activity
is preserved, since the active site of the eukaryotic PFK1s is located
in the N-terminus [12]. However, kinetic characteristics of the
shorter PFK-M fragments are changed (Fig. 5–6). Most important
modified enzymes become insensitive to citrate and ATP
inhibition. By a proteolytic cleavage of the C-terminal part of
the native molecule some components of the citrate binding site
are lost, as well as a motif responsible for the inhibition by ATP
(supplemental Fig. S1). Similar kinetic changes of the modified
PFK1 fragments were also observed after the posttranslational
modification of the native PFK1 enzyme in the filamentous fungus
Aspergillus niger [24]. Isolated, highly active shorter fragments were
resistant to citrate and ATP inhibition, while F-2,6-BP significantly
increased the activities of the shorter fragments but not of the
native PFK1 protein.
All kinetic measurements for human shorter PFK1 fragments
were thus far conducted only in a crude enzyme preparation. It
appeared that cleavage of the C-terminal segments of the
holoenzyme, which is known to stabilize the tetrameric quaternary
structure of the native eukaryotic protein [41], made the
holoenzyme more susceptible to dissociation. In fact, according
to the recently published crystal structure of rabbit skeletal muscle
PFK-M, distal parts of C-teminus are responsible for the formation
of tetrameric holoenzymes. Therefore, it seems very likely that the
shorter fragments, lacking major part of C-terminus can assemble
only in dimmeric forms [42]. Inactivation of PFK1 by dissociation
at low protein concentrations was previously reported and well
characterized for the rat liver enzyme [43]. The extreme instability
of PFK1 appeared to be the major reason that the phenomenon of
posttranslational modification was overlooked until recently.
The efficiency of shorter human PFK1 fragments was also
assessed under in vivo conditions. Interestingly, only fragments
with precise amino acid residue numbers were able to fold into
active holoenzymes in E. coli. Extending the protein chain by one
or two amino acid residues resulted in a complete loss of activity.
These data suggested the need for a specific protease that cleave at
a specific target. Similarly, the accurate length of the shorter
fragments that allowed for enzyme activity was also recorded for
shorter forms of A. niger PFK1 [25]. E. coli transformants that grew
on glucose carried truncated genes of two different lengths and
encoded PFK-M subunits of 45,920 Da (422 amino acid residues)
and 47,825 Da (443 amono acid residues). In fact, these subunits
were the relative molecular masses of both active fragments that
were formed after limited proteolytic digestion of the rabbit PFK-
M and the fragments detected by western blots.
The effect of shorter PFK-M fragments on metabolism was
confirmed by an in vivo test also in mammalian cells. Although
accelerated glucose consumption and lactate production was
detected only at the early time points by the transfectant encoding
the shorter PFK-M fragments, the data suggested the important
role of the modified human PFK-M on de-regulated metabolic
flux through glycolysis. However, no significant increase in growth
rate among various transfectants was observed. It is important to
realize that HEK 293 cell are non-tumorigenic, therefore no
corrupted signal transduction by oncogenic mutations via the
PI3K/Akt/mTOR pathway was present which supported fast
cellular biosynthesis in cancer cells. The decline in glucose
consumption and lactate excretion rate that prevailed after the
first day of incubation of the transfectant encoding Fragment 9,
could be triggered by lactate itself. By comparing metabolic
pathways between cancer cells excreting lactate and non-
tumorigenic stroma cells in colorectal carcinomas [44], it has
been revealed that tumor associated fibroblasts highly expressed
MCT1/2 protein which could capture lactate released from
cancer cells. Stroma cells expressed also high levels of pyruvate
dehydogenase (PDH) that regulated the step from pyruvate to
acetyl CoA, and enable further oxidation of pyruvate. Initially
induced lactate overflow detected in HEK 293 transfectants
encoding the shorter PFK-M fragments (Fig. 6C) might have
triggered similar metabolic changes that were reflected in a
transient increase in lactate excretion.
As previously reported, the insertion of modified pfkA genes
encoding highly active, citrate inhibition-resistant shorter PFK1
fragments enhanced the production of extracellular metabolites in
Figure 7. Growth, glucose consumption and lactate excretion by the stably transfected HEK cells synthesizing PFK1 Fragment 9,
the native PFK-M and HEK cells with empty plasmid. In figure 7A growth of Flp-In T-Rex HEK 293 cells with integrated hpfkMFrg9 (hpfkMFrg9/
HEK - &) encoding the Fragment 9; integrated hpfkM( h pfkM/HEK -N) encoding the native PFK-M enzyme; and cells with integrated empty plasmid
(HEK - e) are presented in logarithmic mode. In figure 7B glucose consumption by transfectants normalized to 1 million cells is shown. In figure 7C
lactate production recalculated to 1 million cells is presented. Identical symbols for individual transfectants are used in all figures. Data are
representative of three independent measurements and are presented as means 6 standard deviation.
doi:10.1371/journal.pone.0019645.g007
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showed substantially accelerated synthesis of citric acid [25],
whereas Aspergillus terreus transformants exhibited faster excretion
of itaconic acid [45]. Both carboxylic acids are primary
metabolites that appear to be transported out of cells to balance
anaplerotic and cataplerotic reactions in cells under the conditions
of deregulated glycolytic flux.
Posttranslational modification of PFK1 enzyme might exhibit
another important role in cancer metabolism. Tumors were
characterized also by the exclusive production of alternatively
spliced M2 form of pyruvate kinase (PKM2). PKM2 differs from
PFK1 in that its activity could be negatively regulated in response
to growth factor signaling by binding to tyrosine-phosphorylated
proteins [10]. However, the concentrations above 20 mMo f
fructose-1,6-bisphosphate (FBP) were able to compete for binding
of recombinant PKM2 to phosphotyrosine peptides and prevented
the inhibition [10]. Even more, FBP has been also shown to act as
a strong stimulator of PKM2 activity [46]. It is hard to believe that
PKM2 was inhibited in tumor cells since about 90% of total
glucose metabolism was accounted for lactate and alanine
production in glioblastoma, therefore undisturbed metabolic flux
through overall glycolysis was necessary [47]. By investigating the
changes of metabolite concentrations during the progression of
normal mouse mammary epithelial cells to an isogenic series of
breast tumor cell lines with increasing metastatic potentials, several
glycolytic intermediates were found to be substantially increased in
tumorigenic lines [48]. One of them was FBP, a product of PFK1
catalytic activity, which concentration was nearly seven fold higher
in the most metastatic cell line (4T1) than in a normal murine
mammary gland epithelial cell line (NMuMG). Such increase of
FBP intracellular concentration could be easily caused by a lack of
feed back inhibition at the level of PFK1, due to the
posttranslational modification of the enzyme.
In conclusion, posttranslational modification of PFK1 might
trigger the most important change in the regulation of glycolytic
flux in cancer cells and might have an important impact on the
Warburg effect. There are indications that the PI3K/Akt signaling
pathway might be involved in the process by activating a specific
proteolytic enzyme that conducts the modifications.
Due to the probable confinement of the shorter PFK1
fragments to cancer cells, they could serve as useful markers for
rapidly growing malignant cells. Because the primary role of the
glycolytic pathway in proliferating cells is believed to be the
synthesis of precursors for cellular building blocks (amino acids,
nucleotides, lipids) [3], the short PFK1 fragments may also
become important targets for uncoupling the synthetic and
energetic pathways in cancer cells.
Materials and Methods
Additional procedures are discussed in Supplementary Data
(Text S1).
Limited proteolytic degradation of rabbit PFK1
Aliquots of 20 ml of purified PFK1 from rabbit skeletal muscle in
a phosphate buffer (pH 7.8) were incubated at 30uC with 1 mlo f
Proteinase K (Sigma-Aldrich, Steinheim, Germany) to give a final
concentration of 0.001 mg/ml. After predetermined incubation
periods, proteolytic activity was blocked by adding 1 ml of PMSF,
a serine protease inhibitor, to reach a final concentration of 1 mM.
Total reaction mixture (22 ml) was then transferred into the
measuring system with 5 mM of citrate and the enzyme activity
recorded by an assay, as described under the supplementary data
(Text S1). As a control, purified rabbit PFK1 was incubated under
the identical conditions without proteolytic enzyme. In addition to
Proteinase K, other proteolytic enzymes were tested at the
following concentrations: Furin, 0.3 to 3.2 U/ml; Cathepsin C,
1 to 10 U/ml; Cathepsin B, 1 to 10 U/ml; Urokinase 1, to 10 U/
ml; and Subtilisin, 0.0001 to 0.1 mg/ml. All proteolytic enzymes
were purchased from Sigma-Aldrich (Steinheim, Germany).
Immunoblotting
Polyclonal rabbit antibody was raised by the GenScript
Corporation (Piscataway, NJ, USA; www.genscript.com) against
the specific epitope (CKDFREREGRLRAA) and purified by
affinity chromatography. This sequence is characteristic of only
mammalian PFK-M enzymes but not the PFK-P and PFK-L
isoforms. Moreover, the search for epitope similarity by BLASTP
(NCBI) [49] revealed that such sequence is confined exclusively to
eukaryotic PFK1 enzymes.
For western blotting, samples of cell line homogenates
containing approximately 20 mg of protein were separated by
SDS-PAGE using 10% polyacrylamide gels with 0.1% sodium
dodecyl sulfate. The transfer of proteins to a nitrocellulose
membrane was confirmed by Ponceau Red. The membrane was
blocked with I-Block reagent (Tropix Inc., Bedford, MA), washed,
and incubated first with a 1:700 dilution of purified primary
antibodies (rabbit polyclonal IgG) and subsequently with a 1:2000
dilution of goat anti-rabbit-HRP secondary antibodies (Abcam,
Cambridge, UK). The membrane was developed with Ilford PQ
Universal paper developer (Harman Technology Ltd., Mobberley,
UK). Molecular mass standards (Santa Cruz Biotechnologies,
Santa Cruz, CA) were used in order to determine the molecular
masses of the PFK fragments. No bands were observed after a
sample of growth medium was immunoblotted with the antibodies
used for PFK1 detection.
DNA manipulation
DNA manipulations were essentially done as described by
Sambrook and Russel [50]. PCR reactions were performed with
PlatinumH Pfx DNA polymerase (Invitrogen, Carlsbad, CA) using
the reaction solution recommended by the manufacturer. DNA
was sequenced by MWG-Biotech AG (Ebersberg, Germany).
Construction of truncated pfkM genes from human pfk-M
cDNA
Human muscle-type PFK1 cDNA (Clone ID2964710) was
purchased from Geneservice Ltd (www.Geneservice.co.uk). Native
human pfk-M was amplified by PCR using 59-AATTATGGATC-
CATGACCCATGAAGAGCACC-39 as a forward primer and 59-
AATTATTCTAGATTAGACGGCCGCTTCCCC-39 as a re-
verse primer. Simultaneously, restriction sites were introduced at
the 59 (BamHI) and 39 (XbaI) ends that enabled cloning into the
pALTER-Ex1 plasmid (Promega, Southampton, UK).
For the construction of truncated human pfk-M genes, BamHI/
XbaI fragments of nine different lengths were prepared by PCR
reactions using the oligonucleotides listed in the table S1 and then
sub-cloned into the pALTER-Ex1 plasmid under the control of
the tac promoter. Finally, the correct nucleotide sequences of the
native gene and all truncated genes were verified.
Transfection of hpfkMFrg9 into non-tumorigenic HEK 293
cells
Fragment 9, encoded by hpfkMFrg9, was cloned into the
pcDNA5/FRT/V5-His TOPO plasmid (Invitrogen, Carlsbad,
CA) by standard PCR-based strategies and confirmed by
sequencing. Transfection of Flp-In T-Rex-HEK293 cells was
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burg, MD). For co-transfection, the pcDNA5/FRT/V5-His
TOPO plasmid with inserted hpfkMFrg9 and the pOG44 plasmid
(Invitrogen, Carlsbad, CA) constitutively expressing Flp recombi-
nase were used. Hygromycin was used as a selective marker at a
concentration of 200 mg/ml.
Un-transfected parental cells were grown in high glucose
DMEM, 10% FBS medium with 100 mg/ml of zeocin and
20 mg/ml of blasticidin. Stably transfected cells with inserted
hpfkMFrg9 were grown in identical medium; however, zeocin was
replaced by 200 mg/ml of hygromycin. As a control, parental
strain transfected with the plasmid without the inserted hpfkMFrg9
gene has been taken.
Supporting Information
Figure S1 Alignment of N- and C- termini of human
PFK-M. Substantial homology can be found among N- and C-
terminus of human PFK-M. Markers below the amino acid
sequence represent: *, identity; : , strongly similarity; ., weakly
similarity. Amino acid residues shown by white letters on black
basis present citrate allosteric binding site [12]. Amino acid
residues at the C-terminus extension marked with grey back-
ground represent the motif responsible for inhibition by ATP [13].
(TIF)
Figure S2 Alignment of the deduced amino acid resi-
dues of the PFK1 active center of human PFK1 proteins
PFK-M (P08237), PFK-P (Q01813), PFK-L (P17858), and
A. niger (P78985) are shown. The threonine (T) residue,
located in the enzyme active center, must be phosphorylated in
order to regain activity of the shorter A. niger PFK1 fragmen [14].
Only the aspartate residue (D) of PFK-M exhibits a negative
charge similar to the phosphorylated threonine in the A. niger
fragment, unlike the alanine residues of the PFK-P and PFK-L
human isoforms (while letters). Allosteric binding sites for ATP are
marked with a gray background.
(TIF)
Figure S3 SDS-PAGE of the native PFK1 after limited
proteolytic degradation by Proteinase K. SDS-PAGE of the
native PFK1 isolated from rabbit muscle revealed the formation of
a 45-kDa fragment after limited proteolysis by Proteinase K. From
left to right: purified native PFK1 from rabbit muscle; Proteinase
K; native PFK1 after limited proteolysis with Proteinase K
(0,001 mg/ml).
(TIF)
Figure S4 Western blot of PFK-M fragments synthesized
in E.coli. Fragments of various length were encoded by a series of
truncated pfkM genes in E.coli strain RL257 lacking its own PFK1
enzymes.
(TIF)
Figure S5 Instability of the shorter PFK-M fragment
under in vitro conditions. PFK1 activity was rapidly lost in the
measuring system with low protein concentration. Data are
presented as means 6 standard deviation.
(TIF)
Table S1 Primers used for the construction of truncated
human pfk genes. Reverse primers used for the construction of
truncated genes of different lengths from human muscle PFK1
cDNA by PCR reaction are shown. In all reactions, the following
oligonucleotide was used as a forward primer: 59-AATTATG-
GATCCATGACCCATGAAGAGCACC-39.
(TIF)
Table S2 Shorter human PFK-M fragments tested in
E.coli. Fragments of specified molecular masses and amino acid
residues encoded by different truncated genes are shown in
columns 1 to 3. Identical fragments would be hypothetically
formed after proteolytic cleavage of the native human PFK1 (type
M) at the specified target sequences (column 4).
(TIF)
Text S1 Supplementary data
(DOC)
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